Suppr超能文献

新辅助化疗联合肝切除治疗多灶性结直肠癌肝转移患者混合病理反应的结果。

Outcomes of Mixed Pathologic Response in Patients with Multiple Colorectal Liver Metastases Treated with Neoadjuvant Chemotherapy and Liver Resection.

机构信息

Department of Surgery, Division of Surgical Oncology, Emory University School of Medicine, Atlanta, GA, USA.

Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.

出版信息

Ann Surg Oncol. 2022 Aug;29(8):5156-5164. doi: 10.1245/s10434-022-11683-1. Epub 2022 Apr 10.

Abstract

BACKGROUND

Pathologic response to preoperative chemotherapy predicts survival in patients with colorectal liver metastases (CLMs) who undergo hepatectomy. In multiple CLMs, mixed pathologic response, wherein tumors exhibit different degrees of treatment response, is possible. We sought to evaluate survival outcomes of mixed response in patients with multiple CLMs.

METHODS

We conducted a retrospective cohort study using a single-institution database of patients with two or more CLMs who underwent preoperative chemotherapy and hepatectomy (2010-2018). Pathologic response of each tumor was measured on pathology. Patients were stratified by pathologic response as complete (pCR) = 0-1% viability; major (pMajR) = 2-49% viability; minor (pMinR) = 50-99% viability; or mixed (pMixR) = at least one pCR/MajR tumor and one pMinR. Recurrence-free survival (RFS) and overall survival (OS) were estimated using the Kaplan-Meier method, and adjusted risk of death was evaluated using Cox regression.

RESULTS

Among 444 patients, 6% had pCR, 34% had pMajR, 36% had pMinR, and 24% had pMixR. Median and 5-year RFS for patients with pMixR was 10.4 months and 16%, respectively, compared with pMajR (11.3 months and 18%, respectively), pMinR (7.7 months and 13%, respectively), and pCR (23.1 months and 38%, respectively) [log-rank p < 0.001]. Median and 5-year OS for patients with pMixR was 77.4 months and 60%, respectively, compared with pMajR (80.5 months and 63%, respectively), pMinR (49.9 months and 39%, respectively), and pCR (median OS not reached; median follow-up of 37.1 months and 5-year OS of 65%) [log-rank p = 0.002]. pMixR was associated with a 52% risk of death reduction (hazard ratio 0.48, 95% confidence interval 0.30-0.78 vs. pMinR).

CONCLUSIONS

One-quarter of patients with multiple CLMs have pMixR following preoperative chemotherapy and hepatectomy. OS and RFS for patients with pMixR mirror those of pMajR rather than pMinR, suggesting the greatest response achieved in any metastasis best predicts survival.

摘要

背景

术前化疗对结直肠癌肝转移(CLM)患者的病理反应可预测接受肝切除术患者的生存情况。在多个 CLM 中,可能存在混合病理反应,其中肿瘤表现出不同程度的治疗反应。我们旨在评估混合反应对多个 CLM 患者的生存结果的影响。

方法

我们使用单一机构数据库进行了回顾性队列研究,该数据库包括接受术前化疗和肝切除术(2010-2018 年)的两个或多个 CLM 患者。每个肿瘤的病理反应均通过病理学进行测量。根据病理反应将患者分为完全缓解(pCR)= 0-1%的活力;主要缓解(pMajR)= 2-49%的活力;次要缓解(pMinR)= 50-99%的活力;或混合缓解(pMixR)=至少一个 pCR/MajR 肿瘤和一个 pMinR 肿瘤。使用 Kaplan-Meier 方法估计无复发生存率(RFS)和总生存率(OS),并使用 Cox 回归评估死亡风险的调整。

结果

在 444 名患者中,6%的患者有 pCR,34%的患者有 pMajR,36%的患者有 pMinR,24%的患者有 pMixR。与 pMajR(分别为 11.3 个月和 18%)、pMinR(分别为 7.7 个月和 13%)和 pCR(分别为 23.1 个月和 38%)相比,pMixR 患者的中位和 5 年 RFS 分别为 10.4 个月和 16%(对数秩 p<0.001)。与 pMajR(分别为 80.5 个月和 63%)、pMinR(分别为 49.9 个月和 39%)和 pCR(中位 OS 未达到;中位随访 37.1 个月和 5 年 OS 为 65%)相比,pMixR 患者的中位和 5 年 OS 分别为 77.4 个月和 60%(对数秩 p=0.002)。pMixR 与死亡风险降低 52%相关(风险比 0.48,95%置信区间 0.30-0.78 与 pMinR 相比)。

结论

接受术前化疗和肝切除术的多个 CLM 患者中有四分之一的患者有 pMixR。pMixR 患者的 OS 和 RFS 与 pMajR 相似,而不是与 pMinR 相似,这表明在任何转移灶中达到的最大反应最好地预测了生存情况。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验